Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

2/2022 vol. 38
Artykuł przeglądowy

Występowanie zespołu Cotarda u pacjentów z niewydolnością nerek leczonych acyklowirem – przegląd literatury

Monika Nowak 1
,
Agnieszka Nowak 2
  1. Faculty of Medicine, Wroclaw Medical University, Wrocław, Poland Wydział Lekarski, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wrocław, Polska
  2. 4th Military Clinical Hospital with a Polyclinic, Independent Public Health Care Facility, Wrocław, Poland 4. Wojskowy Szpital Kliniczny z Polikliniką, Samodzielny Publiczny Zakład Opieki Zdrowotnej, Wrocław, Polska
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (2), 153–159
DOI: https://doi.org/10.5114/fpn.2022.124734
Data publikacji online: 2023/02/09
Plik artykułu
E05R_IPiN_FARM_2022-2B.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Asahi T, Tsutsui M, Wakasugi M et al. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol 2009; 16: 457–60.
  2. Berrios GE, Luque R. Cotard’s syndrome: analysis of 100 cases. Acta Psychiatr Scand 1995; 91: 185–88.
  3. Berry L, Venkatesan P. Acyclovir-induced neurotoxicity: utility of CSF and serum CMMG levels in diagnosis. J Clin Virol 2014; 61: 608–10.
  4. Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, Martín Herranz I. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases. J Clin Pharm Ther 2021; 46: 918–26.
  5. Chiu HFK. Cotard’s syndrome in psychogeriatric patients in Hong Kong. Gen Hosp Psychiatry 1995; 17: 54–5.
  6. Consoli A, Soultanian C, Tanguy ML et al. Cotard’s syndrome in adolescents and young adults is associated with an increased risk of bipolar disorder. Bipolar Disord 2007; 9: 665–68.
  7. Debruyne H, Portzky M, Van den Eynde F, Audenaert K: Cotard’s syndrome: a review. Curr Psychiatry Rep 2009; 11: 197–202.
  8. Dieguez S. Cotard syndrome. Front Neurol Neurosci 2018; 42: 23–34.
  9. Enoch D, Trethowan W. Cotard’s syndrome. In: Uncommon Psychiatric Syndromes, edn 3. Oxford: Butterworth & Heinemann 1991: 162–83.
  10. Figlerowicz M. Acyklowir w terapii przeciwwirusowej. Advances in Dermatology and Allergology / Postępy Dermatologii i Alergologii 2003; 20: 178–82.
  11. Helldén A, Odar-Cederlöf I, Larsson K, Fehrman-Ekholm I, Lindén T. Death delusion. BMJ 2007; 335(7633): 1305. doi: 10.1136/bmj.39408.393137.BE. PMID: 18156240; PMCID: PMC2151143.
  12. Kageyama R, Hashizumi H. Neurotoxicity induced by the recommended acyclovir dosing in a dialysis patient: a case letter. J Dermatol 2016; 43: 339–40.
  13. Kassam AS, Cunningham EA. Cotard Syndrome Resulting From Valacyclovir Toxicity. Prim Care Companion CNS Disord 2018.
  14. Lindén T, Helldén A. Cotard’s syndrome as an adverse effect of acyclovir treatment in renal failure. Journal of the Neurological Sciences 2013; 333: e650.
  15. Marks D, De La Paz A, Walston BJ. Acyclovir-induced neurotoxicity in an immunocompromised patient. SAGE Open Med Case Rep 2020.
  16. Moschopoulos NP, Kaprinis S, Nimatoudis J. Cotard’s syndrome: Case report and a brief review of literature. Psychiatriki 2016; 27: 296–302.
  17. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 2010; 49: 151–57.
  18. Sadjadi SA, Regmi S, Chau T. Acyclovir neurotoxicity in a peritoneal dialysis patient: report of a case and review of the pharmacokinetics of acyclovir. Am J Case Rep 2018; 19: 1459–62.
  19. Salomon J, Szepietowski J. Valaciclovir in the treatment of herpes simplex and herpes zoster infections. Dermatology Review/Przegląd Dermatologiczny 2012; 99: 707–15.
  20. Wei YP, Yao LY, Wu YY, Liu X, Peng LH, Tian YL et al. Critical review of synthesis, toxicology and detection of acyclovir. Molecules 2021; 26: 6566.
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications